Oncology Archives - Page 11 of 22

Phase-specific and lifetime costs of multiple myeloma among older adults in the US

Authors: K Bhattacharya, J P Bentley, S Ramachandran, Y Chang, B F Banahan, R Shah, N Bhakta, Y Yang Published: JAMA Network Open, 2021 View publication Importance Health care costs associated with...

Does biosimilar bevacizumab offer affordable treatment options for cancer patients in the USA? A budget impact analysis from us commercial and Medicare payer perspectives

Authors: J Yang, R Liu, V Ektare, J Stephens, A Shelbaya Published: Applied Health Economics and Health Policy, 2021 View publication Background Bevacizumab remains the most widely used and most thoroughly characterized...

Development of the multiple myeloma symptom and impact questionnaire: a new patient-reported outcome instrument to assess symptom and impacts in patients with multiple myeloma

Authors: K S Gries, J Fastenau, C Seo, B Potrata, C Iaconangelo, D Serrano Published: Value in Health, 2021 View publication Objectives This study aimed to develop and assess the content validity...

Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States

Authors: A Chatterjee, S Shapouri, B S Manzoor, A Ravelo, K Sail, V Qendri, G van de Wetering, M S Davids Published: Blood View publication Introduction Historically chemoimmunotherapy has been the standard...

Cost-effectiveness of a 12-month fixed duration of Venetoclax in combination with Obinutuzumab versus chemoimmunotherapy and other novel combinations in first-line chronic lymphocytic leukemia in Canada

Authors: A Chatterjee, G Van de Wetering, R Goeree, A M Desbois, P Manzi, B S Manzoor, C Owen, K Sail Published: Blood, 2021 View publication Objectives To estimate the cost-effectiveness of...

Phase-specific and lifetime economic burden of cervical cancer and endometrial cancer in a commercially insured United States population

Authors: R Shah, S Corman, A Shah, N Kebede, C Nwankwo Published: Journal of Medical Economics, 2021 View publication Aim To estimate the incremental phase-specific and lifetime economic burden among newly diagnosed...

Estimating and extrapolating survival using a state-transition modeling approach: a practical application in multiple myeloma

Authors: I Majer, S Kroep, R Maroun, C Williams, S Klijn, S Palmer Published: Value in Health, 2021 View publication Objectives State-transition models (STMs) applied in oncology have given limited considerations to...

Evaluation of minimal important difference and responder definition in the EORTC QLQ-PAN26 module for assessing health-related quality of life in patients with surgically resected pancreatic adenocarcinoma

Authors: M Reni, J Braverman, A Hendifar, C P Li, T Macarulla, D Y Oh, H Riess, M Tempero, B Lu, J Marcus, N Joshi, M Botteman, A C Dueck Published: Annals...

Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States

Authors: R Liu , O O Oluwole , I Diakite , M F Botteman , J T Snider , F L Locke Published: Journal of medical economics, 2021 View publication Aims To...

News